. 2021 Mar 13;61(8):1010–1026. doi: 10.1002/jcph.1838
© 2021 Janssen Pharmaceuticals, Inc. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Figure 2.
Rivaroxaban relative safety based on renal function.